Related Experiment Video
Updated: Jun 14, 2025
Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
Published on: March 20, 2020
The treatment landscape of triple-negative breast cancer
Yi Hu1, Chen Wang1, Huishi Liang1
1Beijing Key Laboratory of Gene Resource and Molecular Development, Beijing Normal University, Beijing, China.
Abstract:
Triple-negative breast cancer (TNBC) tumors are biologically aggressive breast cancer. On the molecular level, TNBC is a highly heterogeneous disease; more biotechnologies are gradually being used to advance the understanding of TNBC subtypes and help establish more targeted therapies. Multiple TNBC target-related agents are already approved by the Food and Drug Administration for clinical use, including PI3K/AKT/mTOR inhibitors, PRAP inhibitors, and antibody-drug conjugates. Some innovative approaches, like peptide strategies, also promise to treat TNBC. Currently, the interplay between TNBC tumors and their tumor microenvironment provides a promising prospect for improving the efficacy of immunotherapy. In this review, we summarize the prevalent TNBC subtype methodologies, discuss the evolving therapeutic strategies, and propose new therapeutic possibilities based on existing foundational theories, with the attempt to serve as a reference to further advance tailoring treatment of TNBC.
Insights
Triple-negative breast cancer (TNBC) is aggressive and heterogeneous. This review explores TNBC subtypes, current therapies, and novel strategies targeting the tumor microenvironment for improved immunotherapy efficacy.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Therapeutics
Background:
- Triple-negative breast cancer (TNBC) is characterized by aggressive biological behavior and significant molecular heterogeneity.
- Understanding TNBC subtypes is crucial for developing effective targeted therapies.
- Existing FDA-approved treatments include PI3K/AKT/mTOR inhibitors, PARP inhibitors, and antibody-drug conjugates.
Purpose of the Study:
- To review current methodologies for classifying TNBC subtypes.
- To discuss the evolving landscape of therapeutic strategies for TNBC.
- To propose novel therapeutic avenues by considering the tumor microenvironment and immunotherapy.
Main Methods:
- Comprehensive literature review of TNBC research.
- Analysis of current and emerging therapeutic agents and strategies.
- Exploration of the tumor microenvironment's role in TNBC progression and treatment response.
Main Results:
- TNBC exhibits high heterogeneity, necessitating subtype-specific treatments.
- Targeted therapies and innovative approaches like peptide strategies show promise.
- The tumor microenvironment presents a key area for enhancing immunotherapy efficacy.
Conclusions:
- Tailoring treatment strategies based on TNBC subtypes and molecular characteristics is essential.
- Further research into the tumor microenvironment can unlock new therapeutic possibilities.
- Integrating immunotherapy with other modalities holds potential for improved patient outcomes.
More Related Videos
13:19Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:56Treatment Resistant Cancers
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...